The endogenous opioid system provides an excellent and physiologically relevant example to study redundancy in signaling systems in our body. Over 20 endogenous opioids have been identified, all of which preferentially activate one of three opioid receptors – delta, kappa, and mu opioid receptors – which are all members of the G protein-coupled receptor (GPCR) family of proteins (Gendron et al., 2016; Chavkin, 2013; Williams et al., 2013). All these opioid peptides activate their cognate GPCRs broadly at similar levels in most of the readouts that have been used to measure activation (Sternini et al., 2013). Whether all these opioid peptides are truly redundant or whether they contribute to signaling diversity beyond the initial signaling has been a long-standing question in the field.

Signaling from intracellular compartments, after the initial signaling from the surface, is emerging as a key determinant of the downstream consequences of receptor activation (Irannejad et al., 2013; Yarwood et al., 2017; Eichel and von Zastrow, 2018). While this is still an emerging field, a growing body of evidence suggests that GPCRs are active in endosomes and other intracellular compartments, and that receptors in endosomes can cause distinct signaling outcomes compared to receptors on the cell surface (Vilardaga et al., 2014; Bowman et al., 2016; Stoeber et al., 2018). Receptors rapidly and dynamically move between intracellular compartments and the surface by trafficking. Trafficking could therefore act as a master regulator of GPCR signaling by selectively amplifying signals from specific locations (Weinberg et al., 2019; Hanyaloglu, 2018). Whether physiological systems take advantage of trafficking to localize receptors to different compartments and dictate location-biased signaling, however, is still unanswered.

Here we bridge both questions by asking whether different endogenous opioid peptides can sort receptors to distinct intracellular compartments and drive different location-biased signaling outcomes. Using the kappa opioid receptor (KOR) as a model GPCR, we show that although related Dynorphin peptides can activate KOR on the surface to a similar extent, they induce different trafficking fates and endosomal localization of the receptor. Dyn B predominantly localized KOR to Rab11 recycling endosomes and caused KOR recycling, while Dyn A predominantly localized KOR to late endosomes and caused KOR degradation. Strikingly, Dyn A-activated KOR, but not Dyn B-activated KOR, was in an active conformation in lysosomes and induced cAMP signaling from intracellular compartments. The differences are likely a result of differences in how the peptides activate KOR, as opposed to peptide stability. Our results show that seemingly redundant opioid peptides, which activate receptors on the surface to similar levels, can drive spatially and temporally different signaling outcomes by differentially sorting receptors to distinct endosomal compartments after internalization.

To examine activation and internalization of KOR by Dynorphin peptides we first focused on four physiologically relevant endogenous peptides – Dynorphin A17 (Dyn A), Dynorphin A8 (Dyn A8), Dynorphin B (Dyn B), and ɑ-neoendorphin (ɑ-neo). These peptides differ mainly in their length and C-terminal peptide sequence (Figure 1A). We carried out our studies using neuroendocrine PC-12 cells stably expressing KOR tagged with a pH-sensitive GFP (SpH-KOR) (Sankaranarayanan et al., 2000) that facilitates visualization of agonist-mediated KOR trafficking, and CHO cells stably expressing Flag epitope tagged KOR (CHO-KOR). Consistent with previous findings, we find that in these cells Dyn A, Dyn A8, Dyn B, and ɑ-neo bind KOR at relatively comparable affinities (Table 1).

Figure 1 with 1 supplement see all

Download asset Open asset

Next, we measured the inhibition of cAMP levels and KOR endocytosis induced by these peptides. Dose–response curves with Dyn A and Dyn B in SpH-KOR cells showed maximal inhibition ~1 µM (Figure 1—figure supplement 1A). At this concentration, Dyn A8 and ɑ-neo inhibited whole-cell cAMP to levels comparable to that of Dyn A and Dyn B (Figure 1B). Measurement of cell surface levels of KOR by ELISA show that Dyn A and Dyn B endocytose the receptor to a similar extent in SpH-KOR cells and in CHO-KOR cells (Figure 1—figure supplement 1B and C; Gupta et al., 2016), with maximal endocytosis at ~1 µM. Examination of surface SpH-KOR fluorescence by live cell imaging using Total Internal Reflection Microscopy (TIR-FM) shows similar extent of agonist-mediated KOR clustering into endocytic domains and receptor endocytosis by the four Dynorphin peptides (1 µM) (Figure 1C and D). Together these results indicate that different Dynorphin peptides activate KOR and induce KOR internalization to similar levels.

We next examined if different Dynorphins selectively regulate the fate of KOR after initial activation and internalization, by adapting a discrete-event imaging method to quantitate the rate of individual KOR recycling events over unit time. SpH-KOR fluorescence is quenched in acidic endosomal compartments and is rapidly dequenched when receptors recycle back to the cell surface and are exposed to the extracellular media. This dequenching can be visualized as single events using Total Internal Reflection Fluorescence microscopy (TIR-FM), where the recycling events appear as distinctive sudden spikes in fluorescence followed by an exponential decay as the receptors diffuse on the cell membrane (Figure 2A–C). This method allows us to quantitate individual recycling events in the same cells over time without the confounding effects of continuing endocytosis (Kunselman et al., 2019). When the number of SpH-KOR recycling events were quantitated and normalized to time and cell area, a significantly higher number of recycling events was seen 5 min after Dyn B-induced KOR internalization , compared to Dyn A, Dyn A8, or ɑ-neo (Figure 2D).

Figure 2 with 1 supplement see all

Download asset Open asset

To test whether this increase in the rate of discrete recycling events corresponded to an increase in receptor levels at the cell surface, we measured ensemble changes in surface KOR levels by two different methods – whole-cell fluorescence and ELISA-based methods. We focused on Dyn A and Dyn B as a highly relevant and interesting pair, as both are processed from adjacent regions of pro-dynorphin and are often co-expressed in physiologically relevant brain regions (Nikoshkov et al., 2005; Corder et al., 2018). When SpH-KOR fluorescence was followed by live confocal imaging, surface fluorescence decreased after Dynorphin addition, as was expected with receptor internalization. The fluorescence decrease reached a plateau at 10 min, suggesting an equilibrium between endocytosis and recycling at this time point (Figure 2E). When agonist was removed by washing out the media and replacing with fresh media containing antagonist (naltrexone; 10 µm), to specifically measure recycling without the contribution of endocytosis, the fluorescence recovery rate was higher with Dyn B than with Dyn A at the 30 min time point (Figure 2F and G).

A potential reason for the differences we observe could be differences in the rate of proteolytic degradation of the peptides (Mzhavia et al., 2003; Fricker et al., 2020). Therefore, we directly tested whether inhibiting proteolysis abolishes the difference between Dyn A and Dyn B. We first used a protease inhibitor cocktail in the media to inhibit general proteolysis. When discrete recycling events were quantitated as in Figure 2D, Dyn B showed a higher number of KOR recycling events even in the presence of protease inhibitors (Figure 2—figure supplement 1A). When the recovery of surface KOR levels after agonist washout were measured by an independent ELISA-based method, Dyn B-treated cells showed a higher rate of recovery compared to Dyn A, even in the presence of protease inhibitors (Figure 2H). These experiments indicate that differences in general proteolysis of the peptides did not contribute to the increased KOR recycling we observe with Dyn B. Because Dyn B, but not Dyn A, can be cleaved by Endothelin Converting Enzyme 2 (ECE2) in vitro, we next tested whether this differential proteolysis by ECE2 could contributes to the differences between Dyn A and Dyn B-induced KOR recycling. We used S136492, which inhibits ECE2 relatively selectively in vitro in purified systems (Mzhavia et al., 2003), to test whether ECE2 activity was required for Dyn B to drive increased recycling. S136492 significantly reduced recycling for both Dyn A and Dyn B, indicating that the differences in trafficking between Dyn B and Dyn A cannot be explained solely by ECE2 sensitivity (Figure 2—figure supplement 1B). Together, these results suggest that intrinsic differences between Dyn A and Dyn B contribute to differences in KOR recycling when activated by these peptides.

Because KOR did not recycle efficiently when activated by Dyn A, we next asked whether Dyn A-activated KOR was sorted into the degradative pathway. To test this, PC12 cells expressing SpH-KOR were pretreated with cycloheximide (3 µg/ml) 2 hr before agonist addition to inhibit any new protein synthesis and to measure agonist-mediated turnover of KOR. Total KOR levels were determined through immunoblotting, after Dyn A or Dyn B treatment for 30 min or 2 hr (Figure 2I). When total receptor levels were quantified, 2 hr treatment with Dyn A caused a loss of 50% of KOR, while Dyn B treatment caused no loss (Figure 2J). These results suggest that, after endocytosis, Dyn A preferentially sorts KOR into the degradative pathway, while Dyn B sorts KOR into the recycling pathway.

Considering the emerging importance of spatial encoding in diversifying the outcomes of GPCR signaling (Eichel and von Zastrow, 2018; Weinberg et al., 2019; Hanyaloglu, 2018), we next asked whether Dyn A or Dyn B generated distinctive intracellular localization patterns of KOR at steady state. Because Dyn A drove KOR degradation, we first tested whether Dyn A-activated KOR was differentially localized to the late endosomal pathway. When PC12 cells expressing FLAG-KOR and Rab7-GFP, to mark the late endocytic pathway, were treated with 1 µM Dyn A for 20 min and imaged live, KOR colocalized predominantly with Rab7 (example in Figure 3A). To quantitate the distribution of KOR in the endosomal pathway more comprehensively, we treated cells expressing SpH-KOR with 1 µM Dyn A or Dyn B for 20 min, and fixed and stained for APPL1 (very early endosomes), EEA1 and Rab5 (early endosomes), Rab11 (recycling endosomes), Rab7 (late endosomes), and Lamp1 (lysosomes), as markers for the biochemically distinct compartments along the early, recycling, and late endosomal pathway. Using automated object-picking, we then quantitated the fraction of KOR that colocalized with each endosomal marker under these conditions. KOR localized mainly to compartments marked by Rab7 and Lamp1 when activated by Dyn A, but to compartments marked by EEA1, Rab5, and Rab11 when activated by Dyn B (Figure 3B and C). These results show that KOR is concentrated in different endosomal compartments based on the Dynorphin that activates it.

Figure 3 with 1 supplement see all

Download asset Open asset

The agonist-selective localization of KOR to specific endosomes raised the exciting possibility that different Dynorphins could generate distinct subcellular spatial patterns of KOR signaling. To test this possibility, we combined conformation-selective biosensors and high-resolution imaging of FLAG-KOR to ask whether KOR was active in endosomes. A nanobody (Nb39) that specifically recognizes the active conformation of KOR (Che et al., 2018), when co-expressed with FLAG-KOR in PC12 cells, localized efficiently to endosomes that also contained Dyn A-activated KOR. In contrast, Nb39 localized less to endosomes containing Dyn B-activated KOR (Figure 3D and E). When the fraction of total number of KOR endosomes/cell that colocalized with Nb39 was quantitated by analyzing 3D stacks, endosomes containing Dyn A-activated KOR recruited Nb39 at a significantly higher level (Figure 3F and G), suggesting that KOR was in an active conformation in the endosomes specifically after activation by Dyn A. Nb39 recruitment to endosomes required KOR endocytosis, as recruitment was abolished when cells were treated with agonist in the presence of 40 µM Dyngo4A, an endocytosis inhibitor (Figure 3—figure supplement 1A and B). To directly examine whether Dyn A-activated KOR in lysosomes was in an active conformation, we used three-color live cell imaging of FLAG-KOR, Nb39, and LysoTracker. In cells treated with 1 µM Dyn A, a subset of KOR endosomes colocalized with both Nb39 and Lysotracker. In cells treated with 1 µM Dyn B, however, virtually no KOR endosomes colocalized with both Nb39 and Lysotracker (Figure 3H). When the colocalization was quantitated in Dyn A-treated cells, ~15% of all KOR endosomes colocalized with both markers, suggesting that a subset of Dyn A-activated KOR in the lysosome was in the active conformation (Figure 3I). In contrast, in cells treated with 1 µM Dyn B, virtually no KOR endosomes colocalized with both Nb39 and Lysotracker (Figure 3H).

To test whether the subset of Dyn A-activated KOR in the active conformation in late endosomes and lysosomes was capable of signaling, we measured cAMP inhibition under conditions where the agonist was washed out to avoid continued signaling from the surface. Twenty-five minutes after agonist washout, Dyn A-activated KOR was still localized predominantly to Rab7-labeled late endosomal compartments, while Dyn B-activated KOR was localized predominantly to Rab11-labeled recycling endosomes (Figure 3—figure supplement 1C–H). This distribution was comparable to that observed in the continued presence of agonist, and at this time point, there was little to no KOR degradation (Figure 2I and J). Strikingly, Dyn A, but not Dyn B, caused sustained decrease in cAMP levels under conditions where the majority of KOR was in late endosomes and lysosomes (Figure 3J). Together, our results suggest that Dyn A, but not Dyn B, specifically coordinates activation and cAMP inhibition by KOR in late endosomes and lysosomes.

Importantly, this Dynorphin-selective coordination of KOR recycling and endosomal activation was conserved in striatal neurons. To directly measure KOR recycling, E18 rat primary embryonic striatal neurons were transfected with SpH-KOR, and individual recycling events were imaged using TIRFM. The number of individual exocytic events, when quantified per minute and normalized to cell area, was significantly lower in neurons treated for 30 min with 1 µM Dyn A compared to Dyn B (Figure 4A). This suggested that Dyn B, but not Dyn A, preferentially sorted KOR to recycling endosomes in neurons. We directly tested this by detecting the steady-state localization of KOR in endosomes after Dyn A or Dyn B treatment. KOR colocalized predominantly with Rab7 when activated by Dyn A, and with Rab11 when activated by Dyn B (Figure 4B and C). To test whether this differential localization correlated with differential location-based activation of KOR in endosomes, we expressed Nb33, a distinct nanobody that recognizes the active conformation of opioid receptors (Manglik et al., 2017), fused to GFP in neurons. Endosomes containing Dyn A-activated KOR recruited Nb33, while endosomes containing Dyn B-activated KOR recruited Nb33 to a noticeably lesser extent. This recruitment was readily apparent in dendritic projections, where endosomes were distinctly visible (Figure 4D). The percentage of KOR endosomes that recruited Nb33 was significantly higher for Dyn A-activated KOR than for Dyn B (Figure 4E), showing that dynorphin-selective spatial activation of KOR was conserved in neurons.

Figure 4 with 1 supplement see all

Download asset Open asset

Together, our results reveal an unanticipated difference between physiologically important endogenous opioid peptides in encoding the subcellular spatial patterns of KOR signaling. Peptidases localized to endosomes, like endothelin-converting enzymes (ECEs) may provide another level of regulation for agonist-dependent KOR trafficking (Padilla et al., 2007; Roosterman et al., 2007; Gupta et al., 2015). However, our results do not suggest that ECE peptide-sensitivity is the only or primary factor that determines agonist-dependent KOR localization (Figure 2—figure supplement 1). Ubiquitination of KOR may also regulate its ability to traffic to and signal from late endosomal and lysosomal compartments (Li et al., 2008; Henry et al., 2011; Dores and Trejo, 2019).

The exact mechanism by which KOR is localized to different compartments is not clear. Because the post-endocytic sorting of GPCRs is usually mediated by specific interactions of the unstructured cytoplasmic tail of the receptors with trafficking proteins, KOR sorting probably involves interactions with PDZ-interacting protein NHERF1/EBP50 (Liu-Chen, 2004). In this context, different Dynorphin peptides could lock KOR into conformations that selectively allow or inhibit interactions with trafficking and signaling proteins, essentially defining the receptor interactome in an agonist-specific manner. This conformational lock could require the presence of the ligand that is co-internalized with the receptor, although an exciting possibility is that the ligands provide a ‘conformational memory’ to KOR that is sustained through the endocytic trafficking pathway. At present it is not clear what could provide such a conformational memory. It is possible that different Dynorphins could cause agonist-specific post-translational modifications, which is a general emerging theme for opioid receptors (Chiu et al., 2017; Mann et al., 2019). In any case, the differential subcellular localization and trafficking of KOR by two physiologically important ligands that we show here are important to underscore the physiological relevance of receptor sorting, which has been studied largely using receptor mutants or by depleting key components of the trafficking machinery (Bowman et al., 2016; Weinberg et al., 2019; Zhao et al., 2013; Sposini et al., 2017).

One striking aspect of our results is that Dyn A-bound KOR activates Gi in the late endosomal pathway on its way to being degraded. This is surprising because early endosomes are the main compartments that support endosomal signaling for most other canonical GPCRs. For example, other Gi-coupled receptors such as the mu opioid receptor can exist in an active conformation in earlier endosomal compartments (Stoeber et al., 2018). Internalization is required for sustained inhibition of cAMP for many receptors, such as for the class B S1P receptor (Willinger et al., 2014). However, Gi is likely present on late endosomal and lysosomal compartments, as cannabinoid receptors trafficking from the Golgi can activate Gi on lysosomes (Rozenfeld and Devi, 2008). Further, the binding of peptides to opioid receptors does not change dramatically at lower pH (Gupta et al., 2015). Therefore, it is possible that Gi could be activated at multiple endosomal compartments based on the specific opioid receptor and ligand, leading to distinct early and late phases of endosomal signaling.

Post-translational modifications such as phosphorylation or ubiquitination could provide regulatory handles for this late phase of signaling. For example, three lysine residues on the C-terminus of KOR are required for normal levels of degradation of KOR, but not for internalization from the surface (Li et al., 2008). Ubiquitination, however, plays complex roles in receptor trafficking and signaling at the endosome, controlling transport of receptors to lysosomes, entry of receptors into intralumenal vesicles, and recruitment of signaling scaffolds that could initiate non-canonical signaling pathways (Patwardhan et al., 2021). In this context, Dyn A-activated KOR could also activate alternate pathways, such as mTOR signaling, on late endosomes and lysosomes. Interestingly, mTOR signaling is involved in potentially deleterious effects of KOR, leading to efforts to generate agonists bypassing this signaling pathway (Che and Roth, 2018; Liu et al., 2018; Liu et al., 2019). However, under the conditions we tested, we did not see a significant increase in p70S6 phosphorylation, as a readout for mTOR activation, upon activation of KOR with either Dyn A or Dyn B. This could potentially be due to the high baseline of p70S6 phosphorylation in the PC12 cells (Figure 4—figure supplement 1). However, it is possible that KOR could activate mTOR signaling from late endosomes or lysosomes in a subset of neurons yet to be identified, that could mediate aversive effects of KOR.

Physiological systems could leverage receptor sorting to fine-tune both spatial and temporal aspects of GPCR signaling. KOR is activated by many opioid peptides that are generated from multiple precursor peptidesproteins, some of which bias signaling from the cell surface to different outputs (Gomes et al., 2020). Our results suggest that, even for peptides where there are no obvious differences in surface signaling, there are differential effects in endocytic sorting and signaling from endosomes. Receptor sorting in cells is a dynamic and incomplete process. The fractions of receptors we see at steady state likely represent an equilibrium of many rounds of rapid iterative sorting as the endosome matures, where only a small fraction is recycled back to the surface in the case of Dyn A, while a large fraction is recycled in the case of Dyn B. Because Dyn A drives little KOR to recycle and promotes endosomal KOR activation, the net effect would be to cause a sustained cAMP inhibition from endosomes after a single exposure. Because Dyn B drives KOR recycling and induces endosomal signaling only to small amounts, the net effect would be short-lived cAMP inhibition primarily from the surface. On the other hand, the rapid recycling and resensitization caused by Dyn B would sensitize cells to repeated pulses of ligand release, unlike with Dyn A. This difference in steady-state localization, however, is enough to cause a difference in endosomal receptor activation and cAMP signaling, suggesting that small differences in steady-state localization can cause relevant changes in signaling.

Whether these different Dynorphins are always co-released in the nervous system, or whether different brain regions selectively release specific Dynorphins, is still unclear. Dyn A and Dyn B are generated from prodynorphin likely in the late stages of dense core vesicle maturation and could be predominantly co-released, but there could be mechanisms that actively segregate or selectively release individual Dynorphins. In the case of co-released peptides, it is possible that one or more of the peptides could be dominant in dictating the conformational states in which receptors spend most of their time, in which case the signaling and trafficking fates would be determined primarily by these dominant peptides. In any case, our results that highly related opioid peptides regulate spatial encoding of KOR suggest an unanticipated layer of granularity to the anatomical and functional maps of the brain.

Data generated and analyzed in this study are included in the manuscript. The study did not generate new sequencing or structural data.

1. 1. Bowman SL
   2. Shiwarski DJ
   3. Puthenveedu MA

   (2016) Distinct G protein–coupled receptor recycling pathways allow spatial control of downstream G protein signaling

   Journal of Cell Biology 214:797–806.

   https://doi.org/10.1083/jcb.201512068

   • Google Scholar
2. 1. Chavkin C

   (2013) Dynorphin--still an extraordinarily potent opioid peptide

   Molecular Pharmacology 83:729–736.

   https://doi.org/10.1124/mol.112.083337

   • PubMed
   • Google Scholar
3. 1. Che T
   2. Majumdar S
   3. Zaidi SA
   4. Ondachi P
   5. McCorvy JD
   6. Wang S
   7. Mosier PD
   8. Uprety R
   9. Vardy E
   10. Krumm BE
   11. Han GW
   12. Lee MY
   13. Pardon E
   14. Steyaert J
   15. Huang XP
   16. Strachan RT
   17. Tribo AR
   18. Pasternak GW
   19. Carroll FI
   20. Stevens RC
   21. Cherezov V
   22. Katritch V
   23. Wacker D
   24. Roth BL

   (2018) Structure of the Nanobody-Stabilized active state of the kappa opioid receptor

   Cell 172:55–67.

   https://doi.org/10.1016/j.cell.2017.12.011

   • PubMed
   • Google Scholar
4. 1. Che T
   2. Roth BL

   (2018) Phosphoproteomics illuminates opioid actions

   Biochemistry 57:5505–5506.

   https://doi.org/10.1021/acs.biochem.8b00809

   • PubMed
   • Google Scholar
5. 1. Chiu YT
   2. Chen C
   3. Yu D
   4. Schulz S
   5. Liu-Chen LY

   (2017) Agonist-Dependent and -Independent κ opioid receptor phosphorylation: distinct phosphorylation patterns and different cellular outcomes

   Molecular Pharmacology 92:588–600.

   https://doi.org/10.1124/mol.117.108555

   • PubMed
   • Google Scholar
6. 1. Corder G
   2. Castro DC
   3. Bruchas MR
   4. Scherrer G

   (2018) Endogenous and exogenous opioids in pain

   Annual Review of Neuroscience 41:453–473.

   https://doi.org/10.1146/annurev-neuro-080317-061522

   • PubMed
   • Google Scholar
7. 1. Dores MR
   2. Trejo J

   (2019) Endo-lysosomal sorting of G-protein-coupled receptors by ubiquitin: diverse pathways for G-protein-coupled receptor destruction and beyond

   Traffic 20:101–109.

   https://doi.org/10.1111/tra.12619

   • PubMed
   • Google Scholar
8. 1. Eichel K
   2. von Zastrow M

   (2018) Subcellular organization of GPCR signaling

   Trends in Pharmacological Sciences 39:200–208.

   https://doi.org/10.1016/j.tips.2017.11.009

   • Google Scholar
9. 1. Fricker LD
   2. Margolis EB
   3. Gomes I
   4. Devi LA

   (2020) Five decades of research on opioid peptides: current knowledge and unanswered questions

   Molecular Pharmacology 98:96–108.

   https://doi.org/10.1124/mol.120.119388

   • PubMed
   • Google Scholar
10. 1. Gendron L
    2. Cahill CM
    3. von Zastrow M
    4. Schiller PW
    5. Pineyro G

    (2016) Molecular pharmacology of δ-Opioid receptors

    Pharmacological Reviews 68:631–700.

    https://doi.org/10.1124/pr.114.008979

    • PubMed
    • Google Scholar
11. 1. Gomes I
    2. Filipovska J
    3. Devi LA

    (2003) Opioid receptor oligomerization. Detection and functional characterization of interacting receptors

    Methods in Molecular Medicine 84:157–183.

    https://doi.org/10.1385/1-59259-379-8:157

    • PubMed
    • Google Scholar
12. 1. Gomes I
    2. Gupta A
    3. Filipovska J
    4. Szeto HH
    5. Pintar JE
    6. Devi LA

    (2004) A role for heterodimerization of mu and Delta opiate receptors in enhancing morphine analgesia

    PNAS 101:5135–5139.

    https://doi.org/10.1073/pnas.0307601101

    • PubMed
    • Google Scholar
13. 1. Gomes I
    2. Ijzerman AP
    3. Ye K
    4. Maillet EL
    5. Devi LA

    (2011) G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding

    Molecular Pharmacology 79:1044–1052.

    https://doi.org/10.1124/mol.110.070847

    • PubMed
    • Google Scholar
14. 1. Gomes I
    2. Sierra S
    3. Lueptow L
    4. Gupta A
    5. Gouty S
    6. Margolis EB
    7. Cox BM
    8. Devi LA

    (2020) Biased signaling by endogenous opioid peptides

    PNAS 117:11820–11828.

    https://doi.org/10.1073/pnas.2000712117

    • PubMed
    • Google Scholar
15. 1. Gupta A
    2. Fujita W
    3. Gomes I
    4. Bobeck E
    5. Devi LA

    (2015) Endothelin-converting enzyme 2 differentially regulates opioid receptor activity

    British Journal of Pharmacology 172:704–719.

    https://doi.org/10.1111/bph.12833

    • PubMed
    • Google Scholar
16. 1. Gupta A
    2. Gomes I
    3. Bobeck EN
    4. Fakira AK
    5. Massaro NP
    6. Sharma I
    7. Cavé A
    8. Hamm HE
    9. Parello J
    10. Devi LA

    (2016) Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity

    PNAS 113:6041–6046.

    https://doi.org/10.1073/pnas.1521825113

    • PubMed
    • Google Scholar
17. 1. Hanyaloglu AC

    (2018) Advances in membrane trafficking and endosomal signaling of G Protein-Coupled receptors

    International Review of Cell and Molecular Biology 339:93–131.

    https://doi.org/10.1016/bs.ircmb.2018.03.001

    • PubMed
    • Google Scholar
18. 1. Henry AG
    2. White IJ
    3. Marsh M
    4. von Zastrow M
    5. Hislop JN

    (2011) The role of ubiquitination in Lysosomal trafficking of δ-opioid receptors

    Traffic 12:170–184.

    https://doi.org/10.1111/j.1600-0854.2010.01145.x

    • PubMed
    • Google Scholar
19. 1. Irannejad R
    2. Tomshine JC
    3. Tomshine JR
    4. Chevalier M
    5. Mahoney JP
    6. Steyaert J
    7. Rasmussen SG
    8. Sunahara RK
    9. El-Samad H
    10. Huang B
    11. von Zastrow M

    (2013) Conformational biosensors reveal GPCR signalling from endosomes

    Nature 495:534–538.

    https://doi.org/10.1038/nature12000

    • PubMed
    • Google Scholar
20. 1. Kunselman JM
    2. Zajac AS
    3. Weinberg ZY
    4. Puthenveedu MA

    (2019) Homologous regulation of mu opioid receptor recycling by G _βγ , Protein Kinase C, and Receptor Phosphorylation

    Molecular Pharmacology 96:702–710.

    https://doi.org/10.1124/mol.119.117267

    • PubMed
    • Google Scholar
21. 1. Li JG
    2. Haines DS
    3. Liu-Chen LY

    (2008) Agonist-Promoted Lys63-Linked polyubiquitination of the human κ-Opioid receptor is involved in receptor Down-Regulation

    Molecular Pharmacology 73:1319–1330.

    https://doi.org/10.1124/mol.107.042846

    • PubMed
    • Google Scholar
22. 1. Liu JJ
    2. Sharma K
    3. Zangrandi L
    4. Chen C
    5. Humphrey SJ
    6. Chiu YT
    7. Spetea M
    8. Liu-Chen LY
    9. Schwarzer C
    10. Mann M

    (2018) In vivo brain GPCR signaling elucidated by phosphoproteomics

    Science 360:eaao4927.

    https://doi.org/10.1126/science.aao4927

    • PubMed
    • Google Scholar
23. 1. Liu JJ
    2. Chiu YT
    3. DiMattio KM
    4. Chen C
    5. Huang P
    6. Gentile TA
    7. Muschamp JW
    8. Cowan A
    9. Mann M
    10. Liu-Chen LY

    (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mtor pathway is involved in κ opioid aversion

    Neuropsychopharmacology 44:939–949.

    https://doi.org/10.1038/s41386-018-0155-0

    • PubMed
    • Google Scholar
24. 1. Liu-Chen LY

    (2004) Agonist-induced regulation and trafficking of kappa opioid receptors

    Life Sciences 75:511–536.

    https://doi.org/10.1016/j.lfs.2003.10.041

    • PubMed
    • Google Scholar
25. 1. Manglik A
    2. Kobilka BK
    3. Steyaert J

    (2017) Nanobodies to study G Protein-Coupled receptor structure and function

    Annual Review of Pharmacology and Toxicology 57:19–37.

    https://doi.org/10.1146/annurev-pharmtox-010716-104710

    • PubMed
    • Google Scholar
26. 1. Mann A
    2. Moulédous L
    3. Froment C
    4. O'Neill PR
    5. Dasgupta P
    6. Günther T
    7. Brunori G
    8. Kieffer BL
    9. Toll L
    10. Bruchas MR
    11. Zaveri NT
    12. Schulz S

    (2019) Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists

    Science Signaling 12:eaau8072.

    https://doi.org/10.1126/scisignal.aau8072

    • PubMed
    • Google Scholar
27. 1. Mzhavia N
    2. Pan H
    3. Che FY
    4. Fricker LD
    5. Devi LA

    (2003) Characterization of endothelin-converting enzyme-2. implication for a role in the nonclassical processing of regulatory peptides

    The Journal of Biological Chemistry 278:14704–14711.

    https://doi.org/10.1074/jbc.M211242200

    • PubMed
    • Google Scholar
28. 1. Nikoshkov A
    2. Hurd YL
    3. Yakovleva T
    4. Bazov I
    5. Marinova Z
    6. Cebers G
    7. Pasikova N
    8. Gharibyan A
    9. Terenius L
    10. Bakalkin G

    (2005) Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain

    The FASEB Journal 19:1543–1545.

    https://doi.org/10.1096/fj.05-3743fje

    • PubMed
    • Google Scholar
29. 1. Padilla BE
    2. Cottrell GS
    3. Roosterman D
    4. Pikios S
    5. Muller L
    6. Steinhoff M
    7. Bunnett NW

    (2007) Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and β-arrestins

    Journal of Cell Biology 179:981–997.

    https://doi.org/10.1083/jcb.200704053

    • Google Scholar
30. 1. Patwardhan A
    2. Cheng N
    3. Trejo J

    (2021) Post-Translational modifications of G Protein-Coupled receptors control cellular signaling dynamics in space and time

    Pharmacological Reviews 73:120–151.

    https://doi.org/10.1124/pharmrev.120.000082

    • PubMed
    • Google Scholar
31. 1. Roosterman D
    2. Cottrell GS
    3. Padilla BE
    4. Muller L
    5. Eckman CB
    6. Bunnett NW
    7. Steinhoff M

    (2007) Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to control receptor recycling

    PNAS 104:11838–11843.

    https://doi.org/10.1073/pnas.0701910104

    • PubMed
    • Google Scholar
32. 1. Rozenfeld R
    2. Devi LA

    (2008) Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3

    FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology 22:2311–2322.

    https://doi.org/10.1096/fj.07-102731

    • PubMed
    • Google Scholar
33. 1. Sankaranarayanan S
    2. De Angelis D
    3. Rothman JE
    4. Ryan TA

    (2000) The use of pHluorins for optical measurements of presynaptic activity

    Biophysical Journal 79:2199–2208.

    https://doi.org/10.1016/S0006-3495(00)76468-X

    • PubMed
    • Google Scholar
34. 1. Schindelin J
    2. Arganda-Carreras I
    3. Frise E
    4. Kaynig V
    5. Longair M
    6. Pietzsch T
    7. Preibisch S
    8. Rueden C
    9. Saalfeld S
    10. Schmid B
    11. Tinevez JY
    12. White DJ
    13. Hartenstein V
    14. Eliceiri K
    15. Tomancak P
    16. Cardona A

    (2012) Fiji: an open-source platform for biological-image analysis

    Nature Methods 9:676–682.

    https://doi.org/10.1038/nmeth.2019

    • PubMed
    • Google Scholar
35. 1. Sposini S
    2. Jean-Alphonse FG
    3. Ayoub MA
    4. Oqua A
    5. West C
    6. Lavery S
    7. Brosens JJ
    8. Reiter E
    9. Hanyaloglu AC

    (2017) Integration of GPCR signaling and sorting from very early endosomes via opposing APPL1 mechanisms

    Cell Reports 21:2855–2867.

    https://doi.org/10.1016/j.celrep.2017.11.023

    • PubMed
    • Google Scholar
36. Book

    1. Sternini C
    2. Duraffourd C
    3. Anselmi L

    (2013) Opioids

    In: Sternini C, editors. Handbook of Biologically Active Peptides. Elsevier. pp. 1283–1288.

    https://doi.org/10.1016/C2010-0-66490-X

    • Google Scholar
37. 1. Stoeber M
    2. Jullié D
    3. Lobingier BT
    4. Laeremans T
    5. Steyaert J
    6. Schiller PW
    7. Manglik A
    8. von Zastrow M

    (2018) A genetically encoded biosensor reveals location Bias of opioid drug action

    Neuron 98:963–976.

    https://doi.org/10.1016/j.neuron.2018.04.021

    • PubMed
    • Google Scholar
38. 1. Vilardaga JP
    2. Jean-Alphonse FG
    3. Gardella TJ

    (2014) Endosomal generation of cAMP in GPCR signaling

    Nature Chemical Biology 10:700–706.

    https://doi.org/10.1038/nchembio.1611

    • PubMed
    • Google Scholar
39. 1. Weinberg ZY
    2. Crilly SE
    3. Puthenveedu MA

    (2019) Spatial encoding of GPCR signaling in the nervous system

    Current Opinion in Cell Biology 57:83–89.

    https://doi.org/10.1016/j.ceb.2018.12.006

    • PubMed
    • Google Scholar
40. Software

    1. Weinberg Z

    (2020) IJMacros: object-picker

    Zenodo.

    https://doi.org/10.5281/zenodo.3811031
41. 1. Williams JT
    2. Ingram SL
    3. Henderson G
    4. Chavkin C
    5. von Zastrow M
    6. Schulz S
    7. Koch T
    8. Evans CJ
    9. Christie MJ

    (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance

    Pharmacological Reviews 65:223–254.

    https://doi.org/10.1124/pr.112.005942

    • PubMed
    • Google Scholar
42. 1. Willinger T
    2. Ferguson SM
    3. Pereira JP
    4. De Camilli P
    5. Flavell RA

    (2014) Dynamin 2–dependent endocytosis is required for sustained S1PR1 signaling

    Journal of Experimental Medicine 211:685–700.

    https://doi.org/10.1084/jem.20131343

    • Google Scholar
43. 1. Yarwood RE
    2. Imlach WL
    3. Lieu T
    4. Veldhuis NA
    5. Jensen DD
    6. Klein Herenbrink C
    7. Aurelio L
    8. Cai Z
    9. Christie MJ
    10. Poole DP
    11. Porter CJH
    12. McLean P
    13. Hicks GA
    14. Geppetti P
    15. Halls ML
    16. Canals M
    17. Bunnett NW

    (2017) Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission

    PNAS 114:12309–12314.

    https://doi.org/10.1073/pnas.1706656114

    • PubMed
    • Google Scholar
44. 1. Zhao P
    2. Canals M
    3. Murphy JE
    4. Klingler D
    5. Eriksson EM
    6. Pelayo J-C
    7. Hardt M
    8. Bunnett NW
    9. Poole DP

    (2013) Agonist-biased trafficking of somatostatin receptor 2A in enteric neurons

    Journal of Biological Chemistry 288:25689–25700.

    https://doi.org/10.1074/jbc.M113.496414

    • Google Scholar

Author details

1. Jennifer M Kunselman

   Cellular and Molecular Biology Training Program, University of Michigan Medical School, Ann Arbor, United States

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing

   Contributed equally with

   Achla Gupta

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-9772-4149

2. Achla Gupta

   Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Contributed equally with

   Jennifer M Kunselman

   Competing interests

   No competing interests declared

3. Ivone Gomes

   Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

4. Lakshmi A Devi

   Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

   Contribution

   Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Project administration, Writing - review and editing

   Competing interests

   No competing interests declared

5. Manojkumar A Puthenveedu

   1. Cellular and Molecular Biology Training Program, University of Michigan Medical School, Ann Arbor, United States
   2. Department of Pharmacology, University of Michigan Medical School, Ann Arbor, United States

   Contribution

   Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Visualization, Methodology, Project administration, Writing - review and editing

   For correspondence

   puthenve@umich.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-3177-4231

• 1,878

  views

• 279

  downloads

• 16

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.